|
"Is
There a Business Plan for the Genetic Revolution? While the scientific
world continues to celebrate cracking the human genome, investors and
consumers are taking a more prosaic view. What are the business models
behind g-businesses and who are the value creators? When will we see the
promised wonder drugs and treatments based on these discoveries? Will
public fears, ethical issues and regulatory scrutiny ultimately hold back
the genomics industry?"
|
|
Pascal
Brandys, President and CEO, Biobank, USA
Arthur Caplan, Director, Center for Bioethics, University of Pennsylvania,
USA
William A. Haseltine, Chairman and CEO, Human Genome Sciences, USA
|